"Major Funding Boosts Groundbreaking Cardiovascular Research and Treatment Initiatives"
The Texas Heart Institute has been awarded a $1.14 million grant from the National Heart, Lung, and Blood Institute to develop a novel drug for the treatment of cardiovascular disease. The drug aims to target inflammation associated with atherosclerosis, a leading cause of heart attacks and strokes. Current treatments primarily focus on risk factors after plaque rupture, but this new strategy aims to suppress white blood cell activation within plaques by inhibiting the production of pro-inflammatory mediators. If successful, this first-in-class therapeutic could significantly improve clinical outcomes for cardiovascular patients.
